Brief: Tricida Says Significantly Reducing Its Headcount From 152 To 59 People

Tricida

29/10/2020 11:58

Oct 29 (Reuters) - Tricida Inc  TCDA.O :
    * TRICIDA PROVIDES UPDATE ON FDA INTERACTIONS
    * TRICIDA INC - HELD END-OF-REVIEW CONFERENCE AS A TYPE A
MEETING
WITH DIVISION OF CARDIOLOGY AND NEPHROLOGY OF U.S. FDA ON
OCTOBER 20, 2020
    * TRICIDA INC - BELIEVES FDA WILL REQUIRE EVIDENCE OF
VEVERIMER'S
EFFECT ON CKD PROGRESSION FROM A NEAR-TERM INTERIM ANALYSIS OF
VALOR-CKD TRIAL
    * TRICIDA INC - RE-ORGANIZING COMPANY TO EXTEND ITS
FINANCIAL
RUNWAY IN ORDER TO MAXIMIZE OPTIONS FOR BRINGING VEVERIMER TO
PATIENTS
    * TRICIDA INC -  SIGNIFICANTLY REDUCING ITS HEADCOUNT FROM
152 TO
59 PEOPLE
    * TRICIDA INC - REDUCTION IN HEADCOUNT WILL REDUCE TRICIDA'S
ANNUAL OPERATING COSTS BY APPROXIMATELY $25 MILLION
    * TRICIDA INC - CONTINUES TO BELIEVE THAT ITS CURRENT
DEVELOPMENT
PROGRAM FOR VEVERIMER IS AN APPROPRIATE CANDIDATE FOR
ACCELERATED APPROVAL

Source text for Eikon:  ID:nBw24cQvHa 
Further company coverage:  TCDA.O 

 ((Reuters.Briefs@thomsonreuters.com;))